Theravance Biopharma, Inc. Available-for-sale Securities, Amortized Cost Basis
Theravance Biopharma, Inc. (TBPH) had Available-for-sale Securities, Amortized Cost Basis of $370.96 million as of 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-02-28
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $370.96M.
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $571.81M.
- 2015-12-31: Available-for-sale Securities, Amortized Cost Basis $171.78M; Available-for-sale Securities, Amortized Cost Basis as first filed $172.62M.
- 2014-12-31: Available-for-sale Securities, Amortized Cost Basis $287.58M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2017-12-31 | $370.96M 10-K · filed 2018-02-28 | |
| 2016-12-31 | $571.81M 10-K · filed 2018-02-28 | |
| 2015-12-31 | $171.78M 10-K · filed 2017-03-01 | $172.62M 10-K · filed 2016-03-11 |
| 2014-12-31 | $287.58M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $337.56M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $374.90M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $833.00K 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |